Overview

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Status:
Completed

Trial end date:
2021-07-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Pfizer

Treatments:

Anticoagulants
Apixaban
Asparaginase